Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan's Tolerance in Patients With Metastatic Triple-Negative or Luminal Breast Cancer.

NCT05520723 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT05520723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05520723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan's Tolerance in Patients With Metastatic Triple-Negative or Luminal Breast Cancer.
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
February 6, 2023
Completion date
November 5, 2025
Enrollment
50 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hr+/her2- breast cancer, breast cancer, triple negative breast cancer